Browse trials that we are currently enrolling for by condition and associated pharmaceutical company.
Primary Biliary Cholangitis (PBC)
Cymabay Ideal 32251
Evaluate the effect of seladelpar treatment over 52 weeks compared to placebo on normalization of alkaline phosphatase (ALP) in PBC subjects with an ALP value greater than upper limit of normal (ULN) but less than 1.67×ULN
Ulcerative Colitis(UC)
Abivax – ABX464
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis.
Eli Lilly AMBZ
A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.
Nonalcoholic Steatohepatitis (NASH)
Inventiva
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage 2 or 3.
Crohn’s
Arena(cultivate)
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects With Moderately to Severely Active Crohn’s Disease.
Screening Colonoscopy
Guardant Eclipse
The GuardantLUNAR-2 test is an NGS-based plasma assay which derives a binary qualitative result for a patient’s risk of colorectal cancer. No results from the test will be returned to either the patient or the investigator and therefore no treatment decisions will be based upon the results.
Pill Cam Data Collection
SB3 PillCam (SODA)
Observational, Multicenter, Post-market, Minimal risk, Prospective data collection of PillCam SB3 videos (including PillCam reports) and raw data files and optional collection of Eneteroscopy reports
